{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:24:59Z","timestamp":1790202299118,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.ijantimicag.2005.03.005","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T07:25:42Z","timestamp":1118733942000},"page":"28-32","source":"Crossref","is-referenced-by-count":29,"title":["In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium"],"prefix":"10.1016","volume":"26","author":[{"given":"Alessandro","family":"De Logu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Saddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Onnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenzo","family":"Congiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Borgna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.03.005_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/CMR.9.2.177","article-title":"Epidemiology of infection by nontuberculous mycobacteria","volume":"9","author":"Falkinham","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CMR.6.3.266","article-title":"The Mycobacterium avium complex","volume":"6","author":"Inderlied","year":"1993","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/AAC.45.1.217-222.2001","article-title":"Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium","volume":"45","author":"Bermudez","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","article-title":"Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections","volume":"23","author":"Nuermberger","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/315380","article-title":"Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-bind, placebo-controlled trial. The AIDS Clinical Trials Group 196\/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team","volume":"181","author":"Benson","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.7326\/0003-4819-121-12-199412150-00001","article-title":"Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-bind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team","volume":"121","author":"Chaisson","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib7","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1128\/AAC.42.11.3006","article-title":"Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium","volume":"42","author":"Horgen","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/jac\/49.2.421","article-title":"Rifabutin-induced cystoid macular oedema","volume":"49","author":"Vaudaux","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib9","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1128\/AAC.44.9.2424-2430.2000","article-title":"Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection","volume":"44","author":"Gaspar","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1128\/AAC.45.6.1637-1644.2001","article-title":"Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid","volume":"45","author":"Quenelle","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.40.3.743","article-title":"In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium","volume":"49","author":"Yajko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib12","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1086\/375352","article-title":"Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease","volume":"15","author":"Bermudez","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib13","first-page":"933","article-title":"In vitro activity of thiacetazone on mycobacterial species belonging to the Mycobacterium tuberculosis complex","volume":"6","author":"Abate","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib14","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1128\/AAC.47.8.2685-2687.2003","article-title":"Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice","volume":"47","author":"Bermudez","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0968-0896(01)00310-8","article-title":"Synthesis and antimycobacterial activity of new S-alkylisothiosemicarbazone derivatives","volume":"10","author":"Cocco","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/41.1.77","article-title":"Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages","volume":"41","author":"Sato","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib17","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.43.12.3001","article-title":"Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"43","author":"Tomioka","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/49.2.275","article-title":"Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis","volume":"49","author":"De Logu","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib20","series-title":"Manual of clinical microbiology","article-title":"Susceptibility tests: special tests","author":"Stratton","year":"1991"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib21","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1128\/AAC.40.11.2618","article-title":"Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin","volume":"40","author":"D\u00fczg\u00fcne\u015f","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib22","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","article-title":"Formulation and efficacy of liposome-encapsulate antibiotics for therapy of intracellular Mycobacterium avium infection","volume":"39","author":"Yu-Kyoung","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-200464070-00001","article-title":"Disseminated Mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?","volume":"64","author":"Lange","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-137-9-200211050-00008","article-title":"Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy","volume":"137","author":"Shafran","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/00003495-199448050-00004","article-title":"Current and potential treatment of tuberculosis","volume":"48","author":"Houston","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2005.03.005_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0041-3879(90)90043-8","article-title":"Thiacetazone: in vitro activity against Mycobacterium avium and M. tuberculosis","volume":"71","author":"Heifets","year":"1990","journal-title":"Tubercle"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T01:56:56Z","timestamp":1551059816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0924857905001068"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.03.005","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}